Zymeworks Inc. (ZYME) News
Track canonical SquawkNews coverage tagged to ZYME, Zymeworks Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
US FDA Sets August PDUFA Dates
FDA sets PDUFA dates for several biotech companies
REGULATION | Jul 30, 2026, 03:53 PM UTC
H
Zymeworks price target raised to $31 from $28 at Truist
Truist raised the firm's price target on Zymeworks to $31 from $28 and keeps a Buy rating on the shares as part of a broader research note updating the firm's models and previewing Q2 earnings in Biotech. The firm is ant
EARNINGS | Jul 07, 2026, 01:15 PM UTC
L
Zymeworks shares are trading higher after Wells Fargo raised its price target on the stock from $34 to $37.
Zymeworks shares are trading higher after Wells Fargo raised its price target on the stock from $34 to $37.
EQUITY | Jun 30, 2026, 04:47 PM UTC
L
Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $37
Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ: ZYME ) with a Overweight and raises the price target from $34 to $37.
EQUITY | Jun 30, 2026, 02:24 PM UTC
M
Theravance Biopharma Discloses Termination Fee Of $32.5M After Acquisition Offer By Zymeworks
The Merger Agreement contains certain customary termination rights for the Company and Parent. Subject to the terms and conditions of the Merger Agreement, the Company or Parent may terminate the Merger Agreement if the
MNA | Jun 29, 2026, 10:43 AM UTC
H
Zymeworks To Acquire Theravance Biopharma At $17 Per Share For Total Cash Consideration Of $929M
Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio Acquisition of Theravance Biopharma at
EARNINGS | Jun 29, 2026, 10:04 AM UTC